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ABSTRACT 
 
Adiponectin is an adipokine abundantly expressed in adipose tissue, which has been well 
characterized, demonstrating its beneficial effect on human health, circulates in the bloodstream in 
various isoforms, playing different roles in the balance of energy homeostasis. Adiponectin is an 
insulin sensitizing hormone that exerts its action through AdipoR1, AdipoR2 and T-cadherin 
receptors. AdipoR1 is abundantly expressed in muscle, whereas AdipoR2 is expressed 
predominantly in the liver. Adiponectin is inversely proportional to obesity, diabetes and other states 
of insulin resistance; this review presents current findings regarding regulation, production and 
biological effects. Adiponectin acts by activating AMPk (AMP-activated protein kinase) and thus the 
enzymatic modulation so that the signaling pathways play an important role in the regulation, in 
addition to the above it has been demonstrated that the deregulation in the biogenesis and function 
of the miRNAs contributes to the appearance and development of diverse diseases. 
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ABBREVIATIONS 
 
HER2 : Human epidermal growth factor receptor 2. 
HER3 :  Human epidermal growth factor receptor 3. 
RTKN : Rhotekin coding gene. 
ESR1 : Estrogen receptor coding gene 1.         
ER : Estrogen receptor. 
H-RAS : Gene encoding HRAS proteins. 
HMGA2 : High-mobility group AT-hook 2. 
LIN28 : Encodes a LIN-28 family RNA-binding protein. 
PEBP1 : Encodes a member of the phosphatidylethanolamine-binding family of proteins and 
has been shown to modulate multiple signaling pathways. 
ERBB3 : Receptor tyrosine-protein kinase, also known as HER3. 
CDC25C :  encodes a conserved protein that plays a key role in the regulation of cell division. 
EVI-1 :  Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes. 
BCL-2 : Protein family that regulates apoptosis. 
TIPM1 : Metallopeptidase inhibitor 1.  
PDCD4 : Programmed cell death 4. 
PTEN : phosphatase and tensin homolog. 
MASPIN : mammary serine protease inhibitor. 
RHOA : Family of genes homologous to Ras, member A.  
FOXO2 : Forkhead Box Protein O2.  
E-CADHERIN : Calcium-dependent cell adhesion proteins.  
FOXO3a : Forkhead Box Protein 3A.  
ERα : Estrogen receptor alpha.  
HOXD10 : homeobox D10. 
NF-Kappa B : Nuclear factor kappa-light-chain-enhancer of activated B cells. 
 
1. INTRODUCTION 
 
Obesity is a multifactorial disease produced by 
the interaction of genetic and environmental 
factors, caused by lifestyle, characterized by an 
excessive increase of body fat, produced by an 
imbalance between ingestion and energy 
expenditure [1,2]. Obesity has become a public 
health problem worldwide and its prevalence has 
increased dramatically in developed and 
developing countries [2,3]. In this sense, Mexico 
ranks second in the world prevalence of obesity, 
where over 70% of the adult population is 
overweight and obese, and resulting in economic 
and public health repercussions [4]. 
 
Epidemiological studies have shown that due to 
the physiological condition that occurs in obesity, 
it is a risk factor for the development of different 
diseases, such as cardiovascular, diabetes 
mellitus, hypertension and different types of 
cancer, including breast cancer [1,5]. In this 
sense, accumulation of fat causes a deregulation 
in the production of adipokines which contributes 
strongly to the onset of obesity related to the 
development of various diseases, the 
indisputable protagonist in the pathophysiological 
process of these diseases is adipose tissue, 
which is an endocrine organ that produces 
biologically active molecules defined as 
"adipokines", involved in the homeostasis of 
various physiological processes [6,7]. Therefore, 
alterations in adipose tissue, causes changes in 
the serum concentrations of adipokines, [6] and 
against this background, much of the scientific 
research is directed towards the understanding 
of the pathological mechanisms of obesity, 
allowing to establish clear associations between 
biochemical and anthropometric indicators with 
the risk of complications derived from obesity. 
However, an emerging field is the strong 
relationship between adipokine serum 
concentrations, particularly adiponectin, with 
obesity and its involvement in pathophysiological 
processes [8]. 
 
2. OVERVIEW OF ADIPONECTIN 
 
Adiponectin, one of many hormones secreted by 
adipose tissue, was characterized in the 1990s 
and has received various names according to the 
description of various research groups [9]. 
Plasma concentrations of adiponectin in the 
human are ~ 5-30 μg / ml, this is one of the most 
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abundant proteins in circulation (0.01% of total 
proteins) [10]. The biological effects of 
adiponectin not only depend on blood 
concentrations, but also important the expression 
of different isoforms of receptors in different 
tissues [11].  
 
Adiponectin plays critical roles in metabolism, 
regulation and maintenance for energy 
throughout the body, the main target organs are 
liver and skeletal muscle, however, during the 
last few decades numerous studies have shown 
that adiponectin exerts several effects on other 
organs in different contexts [12] (Fig. 1). 
 
Adiponectin is a 30 kDa protein, composed of 
244 amino acids and encodes the long arm of 
chromosome 3 (locus 3q27). The adiponectin 
gene consists of 3 exons and 2 introns, 
structurally containing 4 domains [15,16], it is 
synthesized as a single subunit and by 
processes of hydroxylation and glycosylation, 
various isoforms circulating in the plasma as 
trimer (low molecular weight LMW), hexamers 
(MMW average molecular weight) or multimers 
(high molecular weight HMW) are originated. The 
monomer form lacks biological activity, whereas 
HMW is the main active form, and is strongly 
associated with insulin resistance, metabolic 
syndrome and cardiovascular disease 
[15,16,17,19]. 
 
The action of adiponectin is mediated by 3 types 
of receptors: AdipoR1, AdipoR2 and T- Cadherin. 
The first two consist of 7 transmembrane 
domains, with the internal N-terminal region and 
the outer C-terminal region, structurally and 
functionally different from the G- protein coupled 
receptor family [15,20]. AdipoR1 is abundantly 
expressed in skeletal muscle and endothelial 
cells, AdipoR2 is expressed predominantly in the 
liver. The third is T-cadherin, lacking a 
transmembrane domain and exhibiting affinity for 
MMW and HMW isoforms, furthermore involved 
in cell adhesion and calcium-mediated cellular 
interactions [14,16,20,21]. 
 
2.1 Signaling Routes 
 
AdipoR1 and ADipoR2 receptors are able to bind 
to adiponectin, their subsequent signaling is 
mediated primarily by AMPK phosphorylation 
and subsequent activation of mTOR (mammalian 
Target of Rapamycin), PI3k (phosphoinositide-3-
kinases) / AKT (protein kinase B), MAPK, PPAR-α 
(peroxisome proliferator-activated receptor 
alpha), STAT3 (Signal transducer and activator of 
transcription 3) and NK-kβ (nuclear factor kappa-
light-chain-enhancer of activated B cells). AMPK 
is activated by the adapter protein APPL-1 
(adaptor protein, phosphotyrosine interaction, PH 
domain and leucine zipper containing 1) and 
kinase β1 (LKB1), the activity of LKB1 (liver 
kinase B1) depends on the interaction with two 
proteins STE 20 (STRAD) and MO25, this 
complex phosphorylates AMPK and regulates 
several pathways, such as apoptosis, 
proliferation, angiogenesis and energy 
metabolism. AMPK phosphorylates the TSC2 
(Tuberous Sclerosis Complex 2) protein, which 
negatively regulates protein synthesis and cell 
proliferation. Adiponectin also affects PI3K / AKT 
signaling, which is involved in cell growth and 
proliferation, AKT phosphorylates TSC2 which in 
turn stimulates mTOR signaling by neutralizing 
the effects of activated AMPK. In treatment with 
adiponectin in breast cancer cells the 
phosphorylation of PI3k and AKT induces the 
activation of AMPK and suppresses the mTOR 
pathway thereby inhibiting cell growth. Low 
doses of adiponectin inhibit ERK1 (extracellular 
signal–regulated kinases) / 2 signaling and 
reduce viability in breast cancer cells, and 
adiponectin induces cell cycle arrest through 
down-regulation of C-myc, cyclin D, and Bcl 
levels. Increases the expression of P53 (cellular 
tumor antigen), P21 (cyclin-dependent kinase 
inhibitor 1) and Bax [22,23,24,25,26]. 
 
2.2 Adiponectin Regulation 
 
White adipose tissue, under normal physiological 
conditions, controls the use of substrates in other 
tissues by releasing hormones such as 
adiponectin that is transported through the 
bloodstream to other organs, where through 
signaling pathways mediated by their receptors, 
they activate key enzymes of lipid and glucose 
metabolism [27]. Both adiponectin receptors 
(Adipor1 and Adipor2), are capable of binding to 
adiponectin; Its subsequent signaling is 
mediated, mainly by the phosphorylation of 
AMPK and the activation of the activated 
receptor of peroxisome alpha proliferator (PPAR), 
in order to exert modifications in the metabolism 
of glucose and lipids of liver and muscle cells, as 
well as in inflammatory processes, vascular 
endothelial injury, and some are associated with 
intracellular signaling such as APPL1. In this 
context, signaling networks play an important 
role in regulation, activating AMPK and thereby 
modulating enzymatic activity at the post-
transcriptional level; and acting on gene 
expression through the PPARS nuclear 
receptors. Similarly, the release of this adipokine 
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has a paracrine effect on the adipocytes 
themselves, in which activation of AMPK also 
occurs, thus establishing a self-regulation of this 
organ [27,28]. 
 
As mentioned above, the control of energy 
metabolism falls to several molecular and cellular 
systems, which interact in a coordinated way 
establishing a network of communication 
between different organs. This explains the 
impact of a disturbance in one of them on the 
whole organism, endocrine-metabolic disorders 
such as obesity, type II diabetes, heart failure, 
characterized by important alterations in energy 
metabolism, are necessarily related to alterations 
in this energy signaling pathway (Table 1). 
 
 
 
Fig. 1. Adiponectin target tissues and cells [13,14,15,16,17,18] 
Increase         Decrease 
 
 
Table 1. Expression inhibitors and main adiponectin signaling ways 
 
Inhibitors of Adiponectin Expression [29, 30, 
31, 32, 33] 
 
TNF-α (Tumor Necrosis Factor alpha) Inhibits the production of adiponectin in adipose 
tissue. 
IL-6 (Interleukin 6) Inhibits the expression and secretion of 
adiponectin genes in 3T3-L1 adipocytes 
CRP (C- reactive protein) Inhibits adiponectin mRNA levels in adipose 
tissue. 
Insulin Suppresses adiponectin gene expression in 
adipocytes. 
Glucocorticoids Suppress adiponectin gene expression in 
adipocytes. 
Β-adrenergic agonists Inhibit adiponectin gene expression. 
 Inhibitors of the Adiponectin Signaling Ways 
AMPK (activaded protein kinase p38) DORSOMORPHIN [34] 
 
 
P38 MAPK (mitogen-activated protein 
kinases) 
SB203580 [35] 
LY2228820 [36] 
VX-702 [37] 
LOSMAPIMOD [38] 
BIRB796 (P38α) [39] 
Skepinone-L(p38 α) [40] 
 HS-173 (P110 α) [41] 
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PI3K (PI3K: phosphatidylinositol 3-kinase) TGX-221 (P110β) [42] 
CZC244832 (P110ϒ) [43] 
CAL-110 (P110δ) [43] 
AKT ( protein Kinase B) A-674563 (AKT 1) [44] 
CCT128930 (AKT 2) [44] 
 
P53 (Cellular Tumor Antigen) 
Pifithrin- α (PFT α) [45] 
ReACp53 [46] 
Pifithrin-µ [47] 
 
3. ADIPONECTIN ASSOCIATED WITH 
PHYSIOPATHOLOGICAL PROCESSES 
 
Adiponectin plays an important role against the 
development of various pathophysiological 
disorders, including metabolic and vascular 
diseases, several endocrine pathologies that 
share some common parameters such as 
increased insulin resistance, obesity and high 
blood glucose levels are closely related to low 
levels of adiponectin. Plasma adiponectin has 
shown a beneficial effect on human health. 
However, low levels of adiponectin in 
pathological conditions such as 
hypoadiponectinemia, is an important risk factor 
for the development of various diseases [48] 
(Table 2). 
 
In contrast to hypoadiponectinemia, 
hyperadiponectinemia is caused by high 
concentrations of plasma asiponectin and leads 
to pulmonary, renal and cardiac diseases 
(Table 3), however, factors contributing to the 
development of hyperadiponectinemia remain 
unknown [62]. 
 
Table 2. Diseases associated with hypoadiponectinemia 
 
 
 
Obesity 
The expression of adiponectin in adipose tissue 
and its plasma concentration is reduced in 
overweight and obese individuals, the plasma 
adiponectin concentration in addition to being 
negatively correlated with body mass index, 
also with the concentration of triglycerides 
[49,50]. 
 
Diabetes Mellitus Type 2 and Resistance to 
Insulin 
Studies conducted in various populations 
revealed that low adiponectin concentrations 
are related to the development of insulin 
resistance and Type 2 diabetes mellitus [51,52]. 
 
Hypertension 
There is a positive correlation between 
hypoadiponectinemia and hypertension, obese 
individuals with low plasma adiponectin levels 
are prone to hypertension [53]. 
 
 
Dyslipidemia 
Dyslipidemia is a disorder of lipid metabolism 
characterized by elevated levels of serum 
triglycerides, low density lipoprotein (LDL 
cholesterol) and low levels of high density 
lipoprotein (HDL) cholesterol. Several studies 
have shown that the level of adiponectin 
indicates an inverse relationship with the level 
of low-density lipoprotein, triglycerides and a 
positive correlation with high-density lipoprotein 
levels [54]. 
 
 
Metabolic Syndrome 
It is a group of conditions, such as abdominal 
obesity, insulin resistance, dyslipidemia, 
hyperglycemia and hypertension, which 
increase the risk of developing diabetes, stroke 
and heart disease. Decreased plasma 
adiponectin levels are associated with an 
increase in the number of metabolic syndrome 
components [55]. 
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Cardiovascular Disease and Aterosclerosis 
Low levels of adiponectin play an important role 
in the development of atherosclerosis and 
cardiovascular disease, due to the fact that 
adiponectin plays a protective role in the 
pathogenesis of vascular diseases by promoting 
the production of nitric oxide, as well as the 
inhibition of inflammation and oxidative stress. 
So adiponectin deficiency shows deterioration 
of endothelium-dependent vasodilation [56, 57]. 
 
Cancer 
Hypoadiponectinenia plays a key role in the 
development and progression of obesity-related 
cancer, low plasma levels of adiponectin are 
directly associated with the risk of developing 
various types of cancer [58, 59, 60]. 
 
 
Hepatic Disease Non Alcoholic  Fat 
Disease caused by the deposition of extra fat in 
liver cells regardless of alcohol consumption 
and can lead to fibrosis and cirrhosis, 
adiponectin limits excess lipid deposition in the 
liver and protects it from inflammation and 
fibrosis, so Hypoadiponectinemia may play a 
crucial role in the progression of non-alcoholic 
fatty liver disease and nonalcoholic 
steatohepatitis [61]. 
 
Table 3. Diseases related to hyperadiponectinemia 
 
 
 
Chronic Renal Disease 
Chronic kidney disease consists of progressive 
loss of renal function over time and is an 
independent risk factor for the development of 
cardiovascular disease. High plasma 
adiponectin levels were found in patients with 
chronic kidney disease compared to healthy 
subjects due to low rate of clearance of 
adiponectin by the kidney [63]. 
 
Lung Disease 
Hyperadiponectinemia is associated with loss of 
body weight, systemic inflammation and 
hyperinflation in patients with COPD [64]. 
 
 
 
 
Chronic Heart Failure 
Adiponectin exerts protective effects on CHF 
(chronic heart failure) and patients with 
cardiovascular disease. However, controversy 
exists over the role of adiponectin and CHF, in 
some studies, high levels of plasma adiponectin 
were found in patients with CHF and increased 
plasma adiponectin levels correlated directly 
with the severity or mortality in CHF despite the 
protective effect of high plasma adiponectin on 
CHF in mice [65]. 
 
3.1 Strategies for Maintaining Healthy 
Plasma Adiponectin Levels 
 
There are several strategies to increase the 
levels of adiponectin although the difficulty of 
converting adiponectin into a viable drug has 
been demonstrated [3]. e.g: PPAR agonists: 
thiazolidinediones (TZD) but TZD: INT131, 
induce the expression of adiponectin [7], in this 
sense a healthy dietary pattern like the 
mediterranean diet increases the adiponectin 
plasma levels, in the same context, the 
activation of AdipoRs is shown one of the most 
promising therapeutic approaches for treating 
disorders related to obesity. Nine agonists have 
recently been demostrated., four of them, 
mataresinol, arctiin, (-) - arctigenin and gramine, 
show a high affinity for AdipoR1. Four of these 
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compounds, parthenolide, taxifolol, 
deoxyschizandrin, syringing, show high affinity 
for AdipoR2 and recently, Okada-Iwabu et al. 
identified a small agonist AdipoRs, AdipoRon 
which, in vitro, binds to AdipoR1 and AdipoR2 
with high affinity [7,66]. 
 
4. REGULATION OF ADIPONECTIN BY 
MICRORNAs 
 
MicroRNAs (miRNAs) are small non-coding 
RNAs that regulate the expression profiles of 
different genes. Consequently miRNAs are key 
molecules in the regulation of various processes 
within which it is possible to cite; proliferation, 
differentiation, mobility, invasion, cell death, 
among others. The miRNAs are sequences of a 
length of 19-25 nucleotides, which regulate the 
transcription of a white RNA, inhibiting its 
translation, stabilizing it or leading to its 
degradation. They are expressed in serum, 
plasma and other body fluids in a stable form, 
which makes them attractive for use as 
biomarkers. Coupled with the above, it is 
demonstrated that deregulation in the biogenesis 
and function of miRNAs contributes to the 
emergence and development of important 
diseases such as diabetes, cardiovascular 
diseases and cancer [67]. 
 
However, there is currently little data available 
on the regulation of adiponectin by miRNAs. 
Adiponectin is a marker protein for the 
expression and secretion of adipose tissue in 
adipocyte differentiation. Studies report that 
miRNAs play an important role in the 
differentiation of adipocytes and in their 
function. For example, in adipocyte 
differentiation, miR-27 expression is down-
regulated, and its overexpression may 
specifically inhibit adipocyte differentiation, miR-
143 expression is upregulated, and the 
inhibition of its expression may reduce 
differentiation of the adipocyte. These data 
suggest that the expression profiles of the 
miRNAs may change the adipocyte 
differentiation. This has been tested by Kang M 
et al. where they report that overexpression of 
some miRNAs such as miR-2 can significantly 
promote adipocyte differentiation, and increase 
the expression of marker genes such as 
adiponectin. Similarly, in an investigation 
conducted by Belarbi et al. observed that 
overexpression of miR-193b, miR-126 and miR-
26a increased secretion of adiponectin in 
human adipocytes [68,69,70]. 
 
5. ROLE OF microRNAs IN BREAST 
CANCER 
 
Among the different types of neoplasias, breast 
cancer is currently the cancer with the highest 
incidence and mortality in the female population 
both in Mexico and worldwide. The 
development of breast cancer is divided into 
initiation, formation, promotion, progression, 
metastasis, therapeutic resistance and 
recurrence of malignant tumors. The miRNAs 
are part of each of these processes and can act 
as oncogenes, tumor suppressors or metastatic 
regulators [71,72,73] (Table 4). 
 
Table 4. Principal miRNAS modulated in breast cancer, white gene and functionality 
 
Tumor suppressor miRNA 
miRNA Target gen Associated function in breast cancer 
miR-125a/b HER2, HER3 Growth dependent anchorage 
miR-145 RTKN, Mucin Its overexpression inhibits the cell growth 
of MCF-7 and induces apoptosis. 
miR-206 ESR1, ER (Decreased in ER- 
positive breast cancer tissues) 
ER signaling 
miR let-7 H-RAS, HMGA2, LIN28, PEBP1 Proliferation, differentiation. 
miR-22  
ERBB3, CDC25C, EVI-1 
Tumor suppressor and metastasis 
inhibitor. 
miRNA oncogenes 
miRNA Target gen Associated function in breast cancer 
miR-21 BCL-2, TIMP1, TIMP3, PDCD4, 
PTEN, MASPIN 
Adiponectin inhibitor 
miR-155 RHOA, FOXO2, E-CADHERIN, 
FOXO3a 
Signaling of TGF-β, inhibitor of apoptosis 
 
miR-125b  
PROAPOPTOTIC Bcl-2 
MiR125b confers resistance to cancer 
cells in the breast cancer to paclitaxel. 
 
 
 
 
Galindo et al.; ARRB, 17(1): 1-11, 2017; Article no.ARRB.36281 
 
 
 
8 
 
miR-22 ERα It represses the expression of 
estrogen receptor α 
miR-206 ERα Induces proliferation 
miR-10b HOXD10 Metastasis 
 
miR-146a/b 
 
NF-Kappa B 
Its deregulation is involved in breast 
cancer; Its increase forms part of the 
altered expression of BRCA1. 
 
To date, several studies have been reported to 
identify differentially regulated miRNAs 
between the tumor and normal mammary 
tissue, suggesting its potential use as disease 
classifiers and prognostic tools in this field. In 
an analysis of 76 breast tumors and 34 normal 
specimens, Lorio et al. identified 29 miRNAs 
that were differentially expressed in breast 
cancer tissue compared to normal [72,73,74]. 
 
6. CONCLUSION 
 
Clinical and experimental studies indicate that a 
normal level of adiponectin helps the body 
counteract various pathologies related to 
obesity, which in turn, triggers the onset of 
metabolic and cardiovascular diseases. 
Alterations in the plasma adiponectin 
concentration are a biomarker useful in obesity, 
diabetes mellitus, dyslipidemia and 
hypertension, so that several studies suggest 
that adiponectin supplementation could be used 
as a potential therapeutic tool, improving the 
expression and function of receptors when they 
are present in pathophysiological conditions 
related to adiponectinemia. Therefore, it is 
necessary to continue studying the effects and 
precise mechanisms of action of adiponectin to 
give way to the development of effective drugs 
aimed at improving the complications 
associated with imbalance of this hormone. 
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